Serum NT‐proCNP levels increased after initiation of GH treatment in patients with achondroplasia/hypochondroplasia

Serum amino‐terminal propeptide of C‐type natriuretic peptide (NT‐proCNP) levels have been proposed as a biomarker of linear growth in healthy children. The usefulness of NT‐proCNP in patients with achondroplasia (ACH)/hypochondroplasia (HCH) remains to be elucidated. The objective was to study whether serum NT‐proCNP level is a good biomarker for growth in ACH/HCH and other patients of short stature.

[1]  A. Aylsworth,et al.  C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia. , 2015, Journal of Clinical Endocrinology and Metabolism.

[2]  M. Polak,et al.  Efficacy and Safety of Growth Hormone Treatment in Children with Hypochondroplasia: Comparison with an Historical Cohort , 2014, Hormone Research in Paediatrics.

[3]  Gabriela A. Vasques,et al.  Role of the Natriuretic Peptide System in Normal Growth and Growth Disorders , 2014, Hormone Research in Paediatrics.

[4]  T. Ogata,et al.  Identification and functional characterization of two novel NPR2 mutations in Japanese patients with short stature. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  T. Cho,et al.  Overgrowth syndrome associated with a gain‐of‐function mutation of the natriuretic peptide receptor 2 (NPR2) gene , 2014, American journal of medical genetics. Part A.

[6]  K. Ozono,et al.  A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B. , 2013, Bone.

[7]  A. Uitterlinden,et al.  An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities. , 2013, Journal of Clinical Endocrinology and Metabolism.

[8]  Gabriela A. Vasques,et al.  Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature in patients initially classified as idiopathic short stature. , 2013, The Journal of clinical endocrinology and metabolism.

[9]  A. Munnich,et al.  Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. , 2012, American journal of human genetics.

[10]  K. Ozono,et al.  Pediatric aspects of skeletal dysplasia. , 2012, Pediatric Endocrinology Reviews: diabetes, nutrition, metabolism.

[11]  K. Chihara,et al.  Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. , 2012, Endocrine journal.

[12]  E. Espiner,et al.  Amino‐terminal propeptide of C‐type natriuretic peptide (NTproCNP) predicts height velocity in healthy children , 2012, Clinical endocrinology.

[13]  H. Yoshikawa,et al.  An Overgrowth Disorder Associated with Excessive Production of cGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 Gene , 2012, PloS one.

[14]  P. Bougnères,et al.  A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia. , 2012, The Journal of pediatrics.

[15]  N. Koles,et al.  Regulation of C-type natriuretic peptide expression , 2011, Peptides.

[16]  Junqi Wang,et al.  Measurement of amino-terminal propeptide of C-type natriuretic peptide in patients with idiopathic short stature or isolated growth hormone deficiency. , 2011, Journal of pediatric endocrinology & metabolism : JPEM.

[17]  K. Nakao,et al.  Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. , 2010, Endocrine journal.

[18]  N. Philip,et al.  A cluster of translocation breakpoints in 2q37 is associated with overexpression of NPPC in patients with a similar overgrowth phenotype , 2007, Human mutation.

[19]  N. Mauras,et al.  Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone, and growth hormone. , 2007, The Journal of clinical endocrinology and metabolism.

[20]  R. Ravazzolo,et al.  Overexpression of the C‐type natriuretic peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced t(2;7) translocation , 2007, Human mutation.

[21]  D. Dickey,et al.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. , 2006, Endocrine reviews.

[22]  I. Kaitila,et al.  Growth hormone treatment in 35 prepubertal children with achondroplasia: A five‐year dose‐response trial , 2005, Acta paediatrica.

[23]  V. Cameron,et al.  Amino-Terminal proCNP: A Putative Marker of Cartilage Activity in Postnatal Growth , 2005, Pediatric Research.

[24]  R. Hammer,et al.  Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Nakao,et al.  Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway , 2004, Nature Medicine.

[26]  Junliang Pan,et al.  Furin-mediated Processing of Pro-C-type Natriuretic Peptide* , 2003, Journal of Biological Chemistry.

[27]  Toshiaki Tanaka,et al.  The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. , 2003, Endocrine journal.

[28]  A. Richards,et al.  Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. , 2001, Biochemical and biophysical research communications.

[29]  K. Nakao,et al.  Dwarfism and early death in mice lacking C-type natriuretic peptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Kanzaki,et al.  Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype. , 1998, European journal of endocrinology.

[31]  Y. Nishi,et al.  Growth hormone therapy in achondroplasia. , 1993, Acta endocrinologica.

[32]  K. Michaelsen,et al.  Predicting and Monitoring of Growth in Children with Short Stature during the First Year of Growth Hormone Treatment , 1991, Acta paediatrica Scandinavica.